
Sickle cell anemia (SCA) is a severe monogenic blood disorder caused by a single point mutation in the β-globin gene, leading to the production of abnormal hemoglobin S and subsequent erythrocyte deformation, chronic hemolysis, and vaso-occlusive crises. Conventional therapies, such as hydroxyurea and blood transfusions, offer symptomatic relief but do not address the underlying genetic defect. Lentiviral gene therapy has emerged as a promising curative strategy, enabling the stable integration of functional β-globin or anti-sickling globin variants into autologous hematopoietic stem cells (HSCs) to restore normal hemoglobin production. Recent advances in vector engineering, promoter optimization, transduction efficiency, and stem cell culture protocols have significantly improved the efficacy and safety profile of this approach. Clinical trials have demonstrated sustained therapeutic hemoglobin expression, reduction in disease complications, and improved quality of life for treated patients. However, critical challenges remain, including high treatment costs, the need for myeloablative conditioning, and limited accessibility in low-resource settings. This review discusses the latest innovations in lentiviral vector technology, preclinical and clinical outcomes, existing limitations, and future directions aimed at broadening the global applicability of this curative therapy.
Background: Acute leukemia is a life-threatening hematologic malignancy marked by the uncontrolled proliferation of immature blood cells in the bone marrow. In low-resource settings such as Sudan, the burden of acute leukemia is compounded by limited diagnostic capabilities, regional healthcare disparities, and a lack of comprehensive cancer registries. Objective: This study aimed to determine the incidence and distribution of acute leukemia specifically Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL) across five major regions of Sudan, with attention to demographic variables such as age and gender. Methods: A descriptive cross-sectional study was conducted using retrospective data from hospital records, hematology registries, and national cancer databases over a five-year period (2020–2024). Data were collected from five regions: Central, Western, Eastern, Northern, and Southern Sudan. Patients of all ages and both genders diagnosed with AML or ALL were included. Incidence rates were calculated and analyzed by region, age group, and sex. Results: Out of a population of approximately 50 million, a total of 364 acute leukemia cases were recorded. The Central Region exhibited the highest incidence rates (ALL: 10.96/million; AML: 7.88/million), while the Northern Region had the lowest (ALL: 1/million; AML: 1.5/million). ALL was predominantly diagnosed in children (94%), whereas AML primarily affected adults (78%). A male predominance was observed in both AML (74%) and ALL (54%). The mean age of presentation was 29.4 ± 14.6 years, with the second and third decades being most affected. Conclusion: Acute leukemia in Sudan shows significant regional and demographic variation, with a concentration of cases in urban areas such as the Central Region. The findings emphasize the need for equitable healthcare infrastructure, improved diagnostic services, and expanded cancer registry coverage, particularly in underserved and remote regions of Sudan.
The clinical demand for bone grafts continues to rise due to trauma, cancer resections, and age-related degeneration, placing significant pressure on current treatment strategies. Autografts remain the gold standard by providing osteogenic cells, extracellular matrix, and osteoinductive signaling, yet their use is limited by donor-site morbidity, finite supply, and additional surgical burden. These constraints have driven the development of synthetic and bioengineered substitutes. Among them, biohybrid bone grafts, biodegradable scaffolds integrated with growth factors, peptides, or stem cells, have emerged as a promising class that combines structural reinforcement with controlled biological activity. This review examines the biological foundations of bone repair and the pathophysiology of critical-sized defects, outlines the limitations of autografts, allografts, and purely synthetic substitutes, and surveys scaffold chemistries (ceramics, polymers, and composites), delivery formats (blocks, granules, moldable putties, and injectables), and representative commercial products across graft classes. Market analysis indicates that the global bone grafts and substitutes sector was valued at approximately USD 3.20 billion in 2024 and is projected to reach USD 5.68 billion by 2034 (CAGR ~5.9%), with North America leading and Asia–Pacific exhibiting the fastest growth. Advances in 3D printing, injectable composites, peptide- and growth factor–enhanced matrices, and stem cell–based constructs are highlighted as key directions shaping next-generation solutions. Together, these insights underscore the need to integrate mechanical integrity, vascularization, and immunomodulation in scalable, off-the-shelf implants that align with minimally invasive surgical workflows and are adaptable to patient-specific anatomy, positioning biohybrid strategies to redefine the treatment of large skeletal defects.
Recent advancements in stem cell biology have accelerated the development of stem cell-based therapies for periodontal tissue regeneration. Twenty-six human clinical studies performed across 10 countries have reported on the use of mesenchymal stem cells (MSCs) for periodontal regeneration, making this approach one of the most thoroughly explored in oral and maxillofacial medicine. Among the various MSC types, dental stem cells (DSCs), including dental pulp stem cells (DPSCs), periodontal ligament stem cells (PDLSCs), and gingival MSCs (GMSCs), have shown advancements due to their accessibility, high proliferation rates, and strong osteogenic potential. Numerous studies have demonstrated the ability of these cells to reduce inflammation, enhance bone regeneration, and restore periodontal tissues. However, continued research and larger clinical trials are needed to fully understand their mechanisms and learn their potential.
Ovarian and breast cancers are the most complex malignancies in women, showing high genetic heterogeneity, dynamic tumor microenvironments, and resistance to conventional therapies. Computer-Aided Drug Design has emerged as a transformative tool that could overcome these challenges by streamlining drug discovery, improving target specificity, and enabling personalized treatment approaches. Techniques such as molecular docking, pharmacophore modeling, and QSAR analysis have helped identify new inhibitors of key targets - HER2, BRCA1/2, PI3K/AKT/mTOR pathways. CADD is also instrumental in optimizing existing therapies, predicting mechanisms of resistance, and repurposing FDA-approved drugs for higher efficacy against cancer-specific pathways. Advances in nanotechnology, combined with CADD, have resulted in the creation of targeted nanocarriers like liposomes and polymeric micelles, allowing for improved delivery of drugs as well as decreasing systemic toxicity. Artificial intelligence and machine learning are currently accelerating the development of multi-targeted therapies and biomarkers towards precision medicine. Despite the present obstacles, tumor heterogeneity, and drug delivery barriers, such continued innovations within CADD technology and experimental validation may revolutionize ovarian and breast cancer treatments towards a more personalized and sustainable therapeutical treatment strategy.